Non-fucosylated Anti-Human IL-5R (Benralizumab) Therapeutic Antibody (CAT#: BioBet-011ZP) Datasheet

IL5RA

interleukin 5 receptor subunit alpha

The protein encoded by this gene is an interleukin 5 specific subunit of a heterodimeric cytokine receptor. The receptor is comprised of a ligand specific alpha subunit and a signal transducing beta subunit shared by the receptors for interleukin 3 (IL3), colony stimulating factor 2 (CSF2/GM-CSF), and interleukin 5 (IL5). The binding of this protein to IL5 depends on the beta subunit. The beta subunit is activated by the ligand binding, and is required for the biological activities of IL5. This protein has been found to interact with syndecan binding protein (syntenin), which is required for IL5 mediated activation of the transcription factor SOX4. Several alternatively spliced transcript variants encoding four distinct isoforms have been reported.

IL5RA; IL5R; Interleukin 5 Receptor Type 3; CDw125; CD125 Antigen; HSIL5R3; Interleukin 5 Receptor, Alpha; IL-5R Subunit Alpha; Interleukin-5 Receptor Alpha Chain; Interleukin-5 Receptor Subunit Alpha; IL-5RA; IL-5 Receptor Subunit Alpha

Membrane; Single-pass type I membrane protein.

Diseases associated with IL5RA include Disseminated Eosinophilic Collagen Disease and Hypereosinophilic Syndrome.

Its related pathways are RET signaling and Signaling by GPCR.

This is the receptor for interleukin-5. The chain binds to IL5.

1.Proteolytically processed under normal cellular conditions. 2.Proteolytically cleaved by caspases during neuronal apoptosis. Cleavage at Asp-739 by either caspase-6, -8 or -9 results in the production of the neurotoxic C31 peptide and the increased production of beta-amyloid peptides. 3. N- and O-glycosylated. 4. Neu5AcNeu5Ac is most likely Neu5Ac 2,8Neu5Ac linked. O-glycosylations in the vicinity of the cleavage sites may influence the proteolytic processing. Appicans are L-APP isoforms with O-linked chondroitin sulfate. 5. Phosphorylation in the C-terminal on tyrosine, threonine and serine residues is neuron-specific. 6. Extracellular binding and reduction of copper, results in a corresponding oxidation of Cys-144 and Cys-158, and the formation of a disulfide bond. In vitro, the APP-Cu(+) complex in the presence of hydrogen peroxide results in an increased production of beta-amyloid-containing peptides. 7. Trophic-factor deprivation triggers the cleavage of surface APP by beta-secretase to release sAPP-beta which is further cleaved to release an N-terminal fragment of APP (N-APP). 8.Beta-amyloid peptides are degraded by IDE.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1

Benralizumab

Mouse

Human

Benralizumab is a humanized recombinant monoclonal antibody that targets the alpha chain of the interleukin 5 receptor (CD125) and was developed by MedImmune.

Severe Eosinophilic Asthma

Not Available

Benralizumab specifically binds to the alpha chain of interleukin 5 receptor (IL-5R) expressed on eosinophils and basophils. IL-5 induces eosinophil-mediated inflammatory responses by binding to the IL-5 receptor (IL-5R) expressed in eosinophils, basophils, and some mast cells. Therefore, the high affinity binding of Benralizumab to the alpha chain domain of IL-5R can block inflammatory signaling and the proliferation of IL-5 dependent cell lines.

Severe Eosinophilic Asthma